CNSP - CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Provides Update on Advances in Brain Cancer Drugs and Operational Financials
- Texas-based CNS Pharmaceuticals is a novel brain cancer drug developer that is building a series of global clinical trials for its lead drug candidate, Berubicin
- CNS began dosing patients in a global trial last September to evaluate Berubicin in treating glioblastoma multiforme (“GBM”), currently an incurable brain cancer
- CNS received FDA Fast Track designation for Berubicin in June 2021 and FDA Orphan Drug designation for Berubicin in June 2020
- Berubicin is a novel anthracycline capable of crossing the blood-brain barrier
- The company received approval from Switzerland’s swissethics organization for Berubicin trials there, boosting CNS’s efforts at a global response to GBM
- Interim evaluation of the first 30-50% of clinical trial participants is expected in early 2023
- A second anthracycline-based chemotherapy agent in development by CNS, WP1244, is progressing in development following synthesis of a new mesylate salt that has led to a new drug candidate named WP1874
- Following a common stock and warrants offering in January, the company’s planned operations are funded into early next year, according to the financial report
Rare cancer researchers at biopharmaceutical CNS Pharmaceuticals (NASDAQ: CNSP) reported advances in regulatory applications and clinical operations in a March 3 announcement that acknowledges expectations for further developments following completion of an $11.5 million private placement round of funding earlier this year.
CNS Pharmaceuticals is developing its lead drug candidate Berubicin as a potential treatment for the aggressive and virtually incurable brain cancer glioblastoma multiforme (“GBM”). Key milestones last year led to the commencement of dosing for the first...
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at http://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text "STOCKS" to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.